



**Cook County COVID-19 Vaccination  
Program Updates  
3/11/2021**



# COVID-19 Surveillance Data

As of March 10, 2021:

**215,672**

Confirmed Cases



**4,047**

Deaths\*



**74**

Weekly Case Rate per 100,000




**3.5%**

Test Positivity Last Week




<https://ccdphcd.shinyapps.io/covid19/>


# COVID-19 Cases by Report Date in Suburban Cook County, IL (n = 215,182)




## COVID-19 Cases by Race/Ethnicity in Suburban Cook County, IL



## COVID-19 Hospitalizations by Race/Ethnicity in Suburban Cook County, IL




## COVID-19 Cases by District in Suburban Cook County, IL



Rate per 100,000 People

## COVID-19 Hospitalizations by District in Suburban Cook County, IL



Rate per 100,000 People



# COVID-19 Vaccine Administration in Suburban Cook County

As of March 10, 2021:

COVID-19 Vaccines Administered to Suburban Cook County Residents

**391,047**

People with at least one vaccine dose

**179,459**

People with complete vaccine series

**17.2%**

Percent of population with at least one vaccine dose

**7.9%**

Percent of population with complete vaccine series

<https://ccdphcd.shinyapps.io/covid19/>



# Pfizer-BioNTech COVID-19 Vaccine

- First ever mRNA vaccine, allowed for rapid development, two doses 21 days
  - Requires ultra-cold (-80C to -60C) storage, must be used within 6 hours after thawing
- 44,000 participants randomized to placebo or vaccine
  - Included 9.3% African American, 4.3% Asian, 28% Latinx, all adults 16 years or older
- Side effects included: injection site pain, fever, fatigue, headache, muscle aches
- Efficacy 95% overall after two doses
  - Similar across age, gender, race, and high risk conditions
  - Full protection two weeks after second dose



## Sources:

<https://www.nejm.org/doi/full/10.1056/NEJMoa2034577> on 12/22/2020

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-11/COVID-02-Gruber.pdf> on 12/13/2020

<https://www.fda.gov/media/144246/download> on 12/13/2020



# Moderna-NIH COVID-19 Vaccine

- Second mRNA vaccine, two doses 28 days apart, no ultra-cold storage required
  - Stable for months in standard freezers, 30 days in refrigerator
- 30,420 trial participants randomized to placebo or vaccine
  - Included 10.2% African American, 4.6% Asian, 20.5% Latinx, all adults 18 years or older
- Side effects included: injection site pain, fatigue, headache, muscle pain, joint pain
- Two doses confer 94% efficacy overall against symptomatic COVID-19
  - Some evidence of protection against asymptomatic COVID-19
  - High ( $\geq 86\%$ ) across age, gender, race, and high risk conditions
  - Full protection two weeks after second dose

## Sources:

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/02-COVID-Miller.pdf> on 12/20/2020

<https://www.fda.gov/media/144434/download> on 12/20/2020





# Johnson & Johnson COVID-19 Vaccine

- Adenovirus-based, single dose, no ultra-cold storage required
  - Stable for two years at -20°C (-4°F), at least three months of which can be at temperatures of 2-8°C (36°F–46°F)
- 43, 783 trial participants randomized to placebo or vaccine
  - Included 19% Black/African American, 3% Asian, 45% Hispanic and/or Latinx; 9% Native American, all adults 18 years or older
  - Some participants infected with emerging COVID-19 variants including variant B.1.351 in South Africa
- Side effects included: safety profile consistent with other vaccine candidates using Janssen's AdVac<sup>®</sup> technology (e.g. approved Ebola vaccine and its Zika, RSV and HIV investigational vaccine candidates)
- Single dose confers 66% overall efficacy against moderate to severe COVID-19 28 days post-vaccination
  - Overall efficacy at preventing moderate to severe COVID-19 by country: 72% in US, 66% in Latin America and 57% in S. Africa (28 days post-vaccination)

Sources:

[Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial | Johnson & Johnson \(jnj.com\)](https://www.jnj.com) 1/29/2021



# Johnson & Johnson COVID-19 Vaccine

## **Prevention of severe disease; Protection against COVID-related hospitalization and death**

- The ENSEMBLE study was designed to evaluate the safety and efficacy of the Janssen vaccine candidate in protecting against both moderate and severe COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints.
  - 85% overall efficacy in preventing severe disease
  - Demonstrated complete protection against COVID-19 hospitalization and death (28 days post-vaccination)
  - 100% efficacy at preventing severe disease (49 days post-vaccination)


Sources:

[Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial | Johnson & Johnson \(nj.com\)](https://www.jnj.com) 1/29/2021



# CDC – Advisory Committee on Immunization Practices (ACIP) Phased Approach for Vaccine Allocation

- Phased implementation with focus on eligible populations for Phase 1a
  - Hospital-based health care workers, highest risk of exposure
  - Long-term care facility (LTCF) residents and personnel
  - Community-based healthcare workers, including EMS personnel





# CDC – Advisory Committee on Immunization Practices (ACIP) Phased Approach for Vaccine Allocation

- **Phase 1b Frontline essential workers and individuals ≥ 65 years (Began vaccination on 1/25)**
  - Frontline essential workers defined as workers who are in sectors essential to the functioning of society and are at substantially higher risk of exposure to COVID-19
- **Phase 1b+ (CCDPH has not moved to this phase yet; anticipate transition in the near future)**
  - Persons aged 16-64 years with high-risk conditions
- **Phase 1c**
  - Essential workers not recommended in Phase 1b
- **Phase 2**
  - All people aged 16 years and older not in Phase 1, recommended for vaccination

For a full list of Phase 1b eligible individuals, please see the bottom of this webpage:

<https://coronavirus.illinois.gov/s/phase-1b>



# Vaccine Strategy

- Partnerships are key to achieving the goal of 70% vaccine uptake required for herd immunity
- Overarching strategy is for healthcare providers in the community to immunize along with mass vaccination events
- Cook County Health with CCDPH are jointly coordinating, immunizing critical populations, and identifying and bridging gaps in coverage
  - CCDPH will continue to monitor testing, contact tracing, vaccination data, and guidance to refine and update allocation strategies





# Vaccine Access Points through Partnerships

- **Federal Pharmacy Program**

- Partnership with CVS and Walgreens to provide vaccine to Long Term Care Facilities

- **Hospitals**

- Vaccinated hospital personnel, some EMTs/Paramedics
- Loyola, Advocate vaccinating 1a and beyond from community

- **Pharmacies**


- Jewel-Osco, Walgreens, Mariano's providing vaccine for Phase 1a and beyond at select sites

- **Community Healthcare Providers**

- Federally Qualified Health Centers (FQHCs), Oak Street Health

- **Schools + EMS/Fire – Hyperlocal sites**

- Planning for frontline essential workers at local level





# Vaccine Access Points Managed by CCH/CCDPH

- **Ambulatory and Community Health Network (ACHN) Health Centers:**
  - 13 locations throughout Cook County, including 6 in suburban Cook County
- **Large vaccination sites:**
  - Tinley Park Convention Center, Tinley Park
  - Triton College, River Grove/Melrose Park
  - South Suburban College, South Holland
  - Des Plaines Vaccination Site
  - United Center, Chicago
  - Additional sites continue to be identified and evaluated with a focus on equity
- **Drive-Through Sites:**
  - Planning for drive-through sites in partnership with Cook County Forest Preserve, as weather improves
- **Mobile Vaccination:**
  - Planning to provide vaccine to specific populations or communities
- **Mobile Vaccination Teams:**
  - Planning to deploy teams of vaccinators to locations where priority groups live or congregate
  - May be staffed by CCDPH, CCH/ACHN, or other partners (Ex: support from Jewel-Osco partnership).



# Cook County Vaccine Appointment Request

COVID-19 Vaccinations at the large-scale community vaccination sites and other Cook County sites will be provided by appointment only and can be scheduled through:

- **Web:** <https://vaccine.cookcountyil.gov/>
- **Phone: 1-833-308-1988** (Monday through Friday, 7am to 7pm)

Cook County is currently in Phase 1b which includes individuals 65 and over and front line essential workers. Vaccine supply is extremely limited at this time. Please be patient.

English Español Vaccine Sign-Up Hotline: [833-308-1988](tel:833-308-1988) M-F 7am-7pm CT

[Sign-up](#) [COVID-19 FAQs](#) [Top Ten Reasons to Be Vaccinated](#) [Pfizer EUA](#) [Moderna EUA](#)

**COVID-19**  
**COMMUNITY VACCINATION PROGRAM**

[Click Here to Sign-Up](#)






# COVID-19 Vaccine Info

en vaccinated. □ CCDPH recently expanded indoor dining to 50 percent capacity, or 50 people, whichever is less. Read the latest Phase 4 mitigation order here. For more information, click here. □ We are currently in Phase 1b

English | Change Language ▾ Vaccine Registration

 Cook County DEPT. of  
**Public Health**  
Promoting health. Preventing disease. Protecting you.


Home COVID-19 ▾ About CCDPH ▾ Programs & Services ▾ How Do I? ▾ Hot Topics ▾ Media Events 🔍

## Vaccination Registration

Cook County Government, Cook County Health and Cook County Department of Public Health are pleased to offer COVID-19 vaccinations to those living or working in Cook County.

Follow the link below to sign up for the vaccine.

[Register for the Vaccine](#)



<https://cookcountypublichealth.org>